AU2008270269B2 - Novel triazene compounds for the treatment of cancer - Google Patents

Novel triazene compounds for the treatment of cancer Download PDF

Info

Publication number
AU2008270269B2
AU2008270269B2 AU2008270269A AU2008270269A AU2008270269B2 AU 2008270269 B2 AU2008270269 B2 AU 2008270269B2 AU 2008270269 A AU2008270269 A AU 2008270269A AU 2008270269 A AU2008270269 A AU 2008270269A AU 2008270269 B2 AU2008270269 B2 AU 2008270269B2
Authority
AU
Australia
Prior art keywords
group
optionally substituted
formula
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2008270269A
Other languages
English (en)
Other versions
AU2008270269A2 (en
AU2008270269A1 (en
Inventor
Heinz Forster
Jochen Kalbe
Rudolf Reiter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trin Therapeutics GmbH
Original Assignee
Trin Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trin Therapeutics GmbH filed Critical Trin Therapeutics GmbH
Publication of AU2008270269A1 publication Critical patent/AU2008270269A1/en
Assigned to TRIN THERAPEUTICS GMBH reassignment TRIN THERAPEUTICS GMBH Request for Assignment Assignors: TRIN PHARMA GMBH
Publication of AU2008270269A2 publication Critical patent/AU2008270269A2/en
Application granted granted Critical
Publication of AU2008270269B2 publication Critical patent/AU2008270269B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/22—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond containing chains of three or more nitrogen atoms with one or more nitrogen-to-nitrogen double bonds
    • C07C245/24—Chains of only three nitrogen atoms, e.g. diazoamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2008270269A 2007-07-04 2008-07-03 Novel triazene compounds for the treatment of cancer Expired - Fee Related AU2008270269B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07111716 2007-07-04
EP07111716.2 2007-07-04
PCT/EP2008/058600 WO2009004060A1 (de) 2007-07-04 2008-07-03 Neue triazenverbindungen zur behandlung von krebs

Publications (3)

Publication Number Publication Date
AU2008270269A1 AU2008270269A1 (en) 2009-01-08
AU2008270269A2 AU2008270269A2 (en) 2012-04-12
AU2008270269B2 true AU2008270269B2 (en) 2013-04-04

Family

ID=38606533

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008270269A Expired - Fee Related AU2008270269B2 (en) 2007-07-04 2008-07-03 Novel triazene compounds for the treatment of cancer

Country Status (13)

Country Link
US (2) US8034797B2 (enExample)
EP (1) EP2167459A1 (enExample)
JP (1) JP2010531855A (enExample)
KR (1) KR20100031620A (enExample)
CN (2) CN102424657A (enExample)
AU (1) AU2008270269B2 (enExample)
BR (2) BRPI0814614A2 (enExample)
CA (1) CA2691178A1 (enExample)
EA (1) EA201000141A1 (enExample)
MX (1) MX2010000223A (enExample)
NZ (1) NZ582346A (enExample)
TW (1) TW200908986A (enExample)
WO (1) WO2009004060A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515734A (ja) * 2011-03-16 2014-07-03 クリエイティブ セラポーティクス ゲーエムベーハー 置換ジフェニル誘導体
WO2012130850A1 (de) 2011-03-31 2012-10-04 Bayer Pharma Aktiengesellschaft Gewebetargeting mit onkoziden verbrückten diphenylderivaten zur selektiven behandlung von sexualorgantumoren
EP2557075A1 (de) 2011-08-09 2013-02-13 Trin Therapeutics GmbH Neue Triazenverbindungen zur Behandlung von Krebs
WO2013041204A1 (de) 2011-09-23 2013-03-28 2LUTION GmbH Neue isocyanat- und isothiocyanat-verbindungen zur behandlung von krebs
CN105566153B (zh) * 2014-10-14 2019-05-31 中国医学科学院药物研究所 偶氮苯衍生物及其制法和药物组合物与用途
CN109776526A (zh) * 2019-01-23 2019-05-21 西南医科大学 稠环三唑-(磺酰基)三氮烯类衍生物及其合成方法和用途
DE102020125641A1 (de) 2020-09-25 2022-03-31 Creative Therapeutics Gmbh Wirkstoffe und Arzneimittel für die Therapie von Viruserkrankungen, insbesondere Corona-Infektionen, insbesondere COVID-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1793115A1 (de) * 1968-08-03 1972-02-03 Bayer Ag Neue Triazenderivate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789138A (fr) * 1971-09-24 1973-03-22 Bayer Ag Nouveaux derives triazeniques, leur procede de preparation et medicament les contenant
DE10324496A1 (de) * 2003-05-30 2004-12-16 Bayer Healthcare Ag Targetorientierte Chemotherapie von Tumoren der Sexualorgane

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1793115A1 (de) * 1968-08-03 1972-02-03 Bayer Ag Neue Triazenderivate

Also Published As

Publication number Publication date
MX2010000223A (es) 2010-04-30
US8426390B2 (en) 2013-04-23
BRPI0814614A2 (pt) 2011-11-29
KR20100031620A (ko) 2010-03-23
AU2008270269A2 (en) 2012-04-12
CA2691178A1 (en) 2009-01-08
BRPI0823332A2 (pt) 2013-07-30
US20100234327A1 (en) 2010-09-16
EP2167459A1 (de) 2010-03-31
EA201000141A1 (ru) 2010-06-30
JP2010531855A (ja) 2010-09-30
AU2008270269A1 (en) 2009-01-08
US8034797B2 (en) 2011-10-11
US20120028927A1 (en) 2012-02-02
WO2009004060A1 (de) 2009-01-08
CN102424657A (zh) 2012-04-25
TW200908986A (en) 2009-03-01
NZ582346A (en) 2012-04-27
CN101796020A (zh) 2010-08-04

Similar Documents

Publication Publication Date Title
US8426390B2 (en) Triazene compounds for the treatment of cancer
AU732723B2 (en) Sulfonylaminocarboxylic acids
US20030220521A1 (en) Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
CN108314663A (zh) 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途
CN111253336B (zh) 治疗癌症的化合物
KR20040091676A (ko) 증식성 질병 치료용 아미노-치환（ｅ）-2,6-디알콕시스티릴 4-치환-벤질설폰
CA2791174A1 (en) Alkylamine derivative
EP0484437A4 (en) Renal-selective prodrugs for the treatment of hypertension
CA2415954A1 (en) Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
CA2829998C (en) Substituted diphenyl derivatives
HK1146481A (en) Novel triazine compounds for treatment of cancer
US8987316B2 (en) Isocyanate and isothiocyanate compounds for cancer treatment
JP2022538074A (ja) タンパク質分解のための化合物、組成物、および方法
EP2086950A2 (en) Histone deacetylase inhibitors
CN118574812A (zh) 苯磺酰胺噻唑化合物及其用于治疗癌症的用途
JPWO2005035471A1 (ja) エーテル誘導体
US12427124B1 (en) Phenylalanine-based LAT1 inhibitors and uses thereof
CN106749009B (zh) 一种培氟沙星醛缩氨基硫脲类衍生物及其制备方法和应用
CN111548286A (zh) 一种具有hdac3抑制活性的psa衍生物及其应用
BR112019000929B1 (pt) Derivados de tiofeno condensados úteis como inibidores de napi-iib, usos dos mesmos, composições farmacêuticas, formulações de dispersão sólida

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ NOVEL TRIAZENE COMPOUNDS FOR THE TREATMENT OF CANCER

PC1 Assignment before grant (sect. 113)

Owner name: TRIN THERAPEUTICS GMBH

Free format text: FORMER APPLICANT(S): TRIN PHARMA GMBH

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 AUG 2011 AND 6 AND 22 MARCH 2012

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application